People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Biotechnology, Pharmaceuticals, Other, Pharma, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Graybug Vision, Inc. | — | Biotechnology | Series C | $144.8M | $132.4M | 2016 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2017 |
| Frontier Medicines Corp | — | Biotechnology | Series C | $122.0M | $2.5B | 2019 |
| Ribon Therapeutics, Inc. | — | Biotechnology | Series B | $119.1M | $342.8M | 2022 |
| Oncorus, Inc. | — | Other | Series C | $115.1M | $921.8M | 2016 |
| Blade Therapeutics, Inc. | — | Biotechnology | Series B | $77.0M | $475.5M | 2016 |
| Vibliome Therapeutics, Llc | — | Pharma | Series A | $8.0M | $247.8M | 2019 |
| MTrap Inc. | — | Biotechnology | Series A | $6.0M | $216.9M | 2016 |
| ZappBug, Inc. | — | Manufacturing | Pre-Seed | $600K | $1.0M | — |
Cameron Wheeler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cameron Wheeler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 3 | 12 |
| Steven Gillis | 1 | 23 |
| Jonathan Root | 1 | 16 |
| Kush Parmar | 1 | 10 |
| Chau Khuong | 1 | 9 |
| Briggs Morrison | 1 | 8 |
| Alon Lazarus | 1 | 7 |
| Brad Smith | 1 | 6 |
| MICHAEL FARRELL | 1 | 6 |
| Christy Shaffer | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Paul Stone | 1 | 5 |
| Mahendra Shah | 1 | 5 |
| Emma Reeve | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| Paul Brannelly | 1 | 4 |
| Jeff Goater | 1 | 4 |
| Eric W. Roberts | 1 | 4 |
| Jeffrey Cleland | 1 | 4 |
| Emmett Cunningham | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.